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Abstract
Background In the Central and Eastern European region, the British EQ-5D-3L value set is used commonly in quality of 
life (QoL) studies. Only Poland and Slovenia have country-specific weights. Our study aimed to investigate the impact of 
value set choice on the evaluation of 18 chronic conditions in Hungary.
Methods Patients’ EQ-5D-3L index scores were calculated using the VAS-based Slovenian and European and the time-trade-
off-based Polish and British value sets. We performed pairwise comparisons of mean index values by dimensions, diagnoses 
and age groups. We evaluated disease burden by comparing index values matched by age and gender in each condition with 
those of the general population of the CEE region in all four value sets.
Results Altogether, 2421 patients (55% female) were included in our sample with the average age of 55.87 years (SD = 17.75). 
The average Slovenian, European, Polish and British EQ-5D-3L scores were 0.598 (SD = 0.279), 0.661 (SD = 0.257), 0.770 
(SD = 0.261) and 0.644 (SD = 0.279), respectively. We found highly significant differences in most diagnoses, with the great-
est difference between the Polish and Slovenian index values in Parkinson’s disease (0.265). Systematic pairwise comparison 
across all conditions and value sets revealed greatest differences between the time-trade-off (TTO) and VAS-based value 
sets as well as varying sensitivity of the disease burden evaluations of chronic disease conditions to the choice of value sets.
Conclusions Our results suggest that the choice of value set largely influences the health state utility results in chronic dis-
eases, and might have a significant impact on health policy decisions.
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Introduction
The burden of chronic diseases is ever increasing as these 
conditions are the main causes of poor health, disabil-
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nowadays [1]. Chronic diseases are often lifelong con-
ditions, which require constant treatment and cause sig-
nificant burden not only on the individual but also on a 
societal level. The introduction of new therapies for the 
treatment of chronic conditions requires knowledge on 
the potential health gains in terms of life years gained or 
improved quality of life. Measuring health-related quality 
of life (HRQoL) in chronic diseases could aid the evalu-
ation of healthcare interventions’ effectiveness and pro-
vide information on the potential health gain that can be 
achieved. Information on potential health gains contributes 
to the better allocation of resources and provides input to 
decision-making.
Evidence on patient’s health-related quality of life can 
be obtained using patient-reported outcome measures, 
some of which are generic, meaning they cover a more 
general spectrum of health problems and are designed to 
be applicable for various health conditions [2]. The EQ-
5D-3L questionnaire is a generic measure of health, which 
is widely used in different countries in a variety of clinical 
areas. The EQ-5D-3L questionnaire can be used to derive 
Health Utility Index scores [3]. The utility values that are 
attached to the health states described by the question-
naire can be used in health economic analysis to quantify 
the possible health gains expressed in quality-adjusted life 
years (QALYs) [4].
For the valuation of the EQ-5D-3L health profiles, dif-
ferent value sets are applicable. However, not all coun-
tries have their own value set: in the Central and Eastern 
European (CEE) regions, only Slovenia and Poland have 
country-specific value sets. In health economic analyses as 
well as the assessment of the health status of the general 
population, in other countries of the CEE region, usually, 
the British TTO value set is used [5–8]. The European 
value set was derived from six countries [9], to be used 
in multinational studies in Europe. However, it is not fre-
quently used in the CEE region. [8].
Previous studies indicate that differences are present 
between results calculated with different value sets and 
that it may be attributed to societal and cultural differ-
ences. The relative importance of the problems reported 
in the five EQ-5D dimensions differs by value sets [10], 
and certain conditions differ largely in the frequency of 
problems reported in the various EQ-5D dimensions. 
Therefore, differences in the country-specific value sets 
may lead to significantly different EQ-5D index scores and 
thus differences in utility values among different disease 
conditions. As the utilities are often used in health eco-
nomic analyses, the use of different value sets may lead to 
disparities and significant differences in health priority set-
ting and decision-making. Comparative analyses have been 
conducted to determine how the choice of value sets might 
affect the assessment of population health [11], QALY 
calculations in patient samples [12] or the assessment of 
health state transitions [13]. Furthermore, the measure-
ment properties of EQ-5D-5L and 3L value sets from sev-
eral countries have been compared in eight disease groups. 
[14] However, we were not aware of studies exploring the 
systematic differences between value sets across multiple 
disease conditions and their potential impact on disease 
burden evaluations and health priority setting.
We aimed to compare the Slovenian, Polish, British and 
European EQ-5D-3L value sets, which are most commonly 
used or are potentially applicable for health economic evalu-
ations in the CEE region. Our study was based on the com-
parative analysis of patient-level data from cross-sectional 
surveys conducted in Hungary among patient populations 
in 18 different chronic conditions. We explored the differ-
ences of the EQ-5D-3L index scores calculated with the four 
value sets by diagnosis, age group and disease severity. Fur-
thermore, we analysed the potential impact of the choice of 
value sets on health priority setting by comparing the disease 
burden evaluations across different conditions using differ-
ent value sets.
Methods
EQ‑5D‑3L
The EQ-5D-3L questionnaire is a health status measure 
that consists of two parts, a descriptive system and the EQ 
VAS. The descriptive system focuses on five dimensions of 
health: mobility (MO), self-care (SC), usual activities (UA), 
pain/discomfort (PD) and anxiety/depression (AD). In each 
dimension, there are three response categories (1, 2 or 3) 
representing: no problems—1, moderate problems (some 
problems in MO, SC and UA; moderate PD and AD)—2; 
severe problems (unable MO, SC and UA, extreme PD and 
AD)—3. Respondents are asked to indicate for each dimen-
sion the level of problem that best describes their current 
health status [5, 15]. The responses (1, 2 or 3) for the five 
dimensions can be combined into a five-digit number that 
describes the respondent’s health state (e.g. no problem 
in any of the five dimensions can be described as 11111; 
some problems in Mobility but no problem in the other four 
dimensions is presented as 21111). The descriptive system 
can define 243 different health states. To each health state, 
an EQ-5D-3L index score can be attached according to a 
particular set of preference weights, also called value set. 
The EQ-5D-3L index score (value) reflects the relative util-
ity (desirability) of the health state and can be used for the 
calculation of quality-adjusted life years (QALY) in cost-
utility analyses [4]. The second part of the questionnaire is a 
visual analogue scale (EQ VAS) ranging from 0 (represent-
ing the worst imaginable health) to 100 (best imaginable 
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health state) on which respondents rate their current health 
state.
EQ‑5D‑3L value sets
EQ-5D-3L value sets have been developed in various coun-
tries based on preferences of the general population using 
direct methods such as time-trade-off (TTO) and EQ-5D vis-
ual analogue scale (EQ-VAS, hereinafter VAS) or both [16]. 
In the TTO exercise, respondents have to decide between 
two alternative outcomes. Generally, the question refers to 
whether they would be willing to exchange a certain life 
expectancy to a shorter one lived in perfect health [17]. In 
the VAS-based valuation, respondents have to locate the 
different health states as well as death on the 0–100 VAS, 
where 0 is the worst and 100 is the best imaginable health 
state. The differences between the positions of the health 
states marked on the VAS should correspond to the differ-
ences in preference as perceived by the respondent.
In our study, we compared four value sets. The Brit-
ish valuation study was conducted in 1993. From 6080 
randomly selected addresses, 2997 respondents provided 
complete data for evaluation. The value set was determined 
by the valuation of 42 health states in a face-to-face TTO 
exercise in addition to “full health” (11111) and “death”. 
Each respondent valued 13 health states. [7]. A VAS-based 
European value set was published in 2003 [9]. It was derived 
from 11 surveys carried out between 1991 and 1999 in Fin-
land (one study), Germany (three studies), The Netherlands 
(one study), Spain (three studies), Sweden (two studies) 
and the UK (two studies), with a total of 6870 respondents 
[18–28]. The preference weights were estimated from the 
valuations of 44 EQ-5D health states. In the individual stud-
ies, various combinations of the 44 health states were val-
ued. However, most studies valued a core set of 13 health 
states in addition to full health and death, and each of the 
44 states were valued in at least two studies. [9]. The Polish 
valuation study was performed in 2008 on a sample of 321 
visitors of inpatients in eight hospitals using quotas to ensure 
a representative sample of the adult population of Poland. 
The TTO exercise was conducted during face-to-face inter-
views, and 45 health states were valued in addition to 11111 
and “dead”. Each respondent valued 25 health states. [29]. 
The Slovenian value set was determined in 2000 in a postal 
survey. The survey involved 3000 adults randomly selected 
from the general population. After checking logical con-
sistency, answers returned by 370 individuals (12.3%) were 
used in the valuation exercise. In addition to “dead” and 
“unconscious”, each respondent valued the same 14 health 
states using the VAS [30]. The EQ-5D-3L index score range 
of the four value sets are as follows: Slovenian − 0.225 to 1; 
European − 0.074 to 1; Polish − 0.523 to 1; British − 0.594 
to 1.
Sample
This current study is a secondary analysis of 18 previous 
surveys conducted by the Department of Health Economics 
of the Corvinus University of Budapest in the past 14 years 
[8, 31–48]. We selected those studies which used the vali-
dated Hungarian version of the EQ-5D-3L questionnaire for 
the assessment of patients with chronic conditions. We only 
included those patients in our analysis, who had answers 
in all five EQ-5D-3L dimensions; hence EQ-5D-3L index 
scores could be calculated using the four different value sets. 
The 18 datasets were combined into a pooled sample.
Statistical analysis
We applied descriptive methods and graphical representation 
of key findings. As sample sizes varied substantially across 
the datasets (min: N = 61, max: N = 249), analytical weights 
were constructed to make the pooled dataset a balanced sam-
ple of the 18 diseases. The sum of weights was set to 100 by 
each condition. We calculated weighted mean and percent-
age values when reporting characteristics of the pooled sam-
ple totals. We compared the four value sets by (1) EQ-5D-3L 
dimensions, (2) by diagnosis, (3) by respondents’ subjec-
tive health assessment (EQ VAS) and (4) by age group, 
according to the following. (1) When comparing value 
sets by EQ-5D-3L dimensions, we graphically represented 
indices of health states with moderate and severe levels of 
isolated problems in each dimension (e.g. 21111, 31111, 
etc.), as well as the combinations of moderate and severe 
problems (21122, 22222, 32233, 33333) against full health 
(11111). This comparison allows us to take into account 
the full disutility arising from the severity of problems and 
the dimension-specific preferences [10]. (2) Although the 
distribution of index values was not normal, the sample size 
was sufficiently large to allow the comparison of diagnosis 
subgroups using two-sided paired t tests [49]. (3) To assess 
the differences between value sets depending on disease 
severity, we plotted the four value sets against respondents’ 
subjective health assessment. We obtained EQ VAS scores 
from each patient in addition to the EQ-5D-3L health pro-
files. To balance frequency peaks at round EQ VAS values, 
yet retain granularity, we divided patients into 36 quantiles 
based on EQ VAS scores, and represented visually mean 
index values of the four value sets in each EQ VAS quan-
tile. (4) When comparing value sets across age groups, we 
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applied a weighted OLS regression model with standard 
errors clustered at the individual patient level.
Finally, for each value set, we calculated disease bur-
den (DB) scores and the sensitivity of DB evaluations to 
the choice of value set. DB was defined as the difference 
between the average health status of the patient group and 
health state of the general population comparable by age 
and gender. For DB score calculations, we used the popula-
tion norm values estimated from a joint database of Polish, 
Slovenian and Hungarian population studies (n = 6926), 
by calibrating to the 2011 European population census by 
age, gender and education [50]. We expressed DB scores as 
disutilities. For instance, a 0.2-point DB score over a year 
represents 0.2 QALY loss compared to the comparable gen-
eral population.
From the 18 samples, we modelled the effect of the choice 
of the value set on DB evaluations. We calculated a sensi-
tivity index according to the following procedure. First, we 
performed all pairwise DB comparisons for each condition 
using the four value sets. Each i condition was compared 
to the other 17 j conditions (i ≠ j). In each comparison with 
value set k (Slovenian, European, Polish or British), the dif-
ference between  DBi and  DBj (ΔDBijk) could be significantly 
positive (+), non-significant (0) or significantly negative (−). 
Second, we evaluated how consistent ΔDBij1···ΔDBijk were 
across the k value sets. In case of consistent difference, the 
pattern was identical for all four value sets (++++ , 0000 
or −−−−). In case of inconsistent difference, the outcome 
was diverse (e.g. 0 + 00, or 00−−). When comparing value 
set pairs, then the pattern of difference was assessed on two 
ΔDBij pairs (k = 2). The pattern of consistent difference was 
++, 00 or −−, while examples of inconsistent difference 
were 0 + , −0 or +−, etc. Finally, the sensitivity index was 
expressed as the proportion of diverse outcomes among all 
pairwise comparisons. We calculated sensitivity indices by 
comparing the four value sets for each diagnosis as well as 
for the total sample. These sensitivity indices can be inter-
preted as a general measure of how sensitive the DB evalu-
ations are to the choice of a value set. For each diagnosis, 
the general sensitivity index calculation was based on 17 
diagnosis pairs and four value sets  (DBij n = 17, k = 4). For 
the sample total, the general sensitivity index calculation 
was based on 153 diagnosis pairs and four value sets (ΔDBij 
n = 18*17/2, k = 4). The pairwise sensitivity indices express 
for each diagnosis how sensitive the DB evaluations are to 
the choice between two particular value sets  (DBij n = 17, 
k = 2), as well as how sensitive the sample total is to the 
choice between two particular value sets  (DBij n = 18*17/2, 
k = 2). Table 3 summarises the sensitivity indices denot-
ing the calculation methods. When interpreting the results, 
greater sensitivity index values represent a greater share of 
inconsistent comparisons or greater sensitivity to the value 
set choice.
Results
Sample characteristics
The 18 chronic conditions belonged to nine different ICD-
10 (International Statistical Classification of Diseases and 
Related Health Problems 10th Revision) groups. The total 
sample included 2421 patients with psoriatic arthritis (PsA) 
[31], age-related macular degeneration (AMD) [32], atten-
tion-deficit/hyperactivity disorder (ADHD) [33], dementia 
[34], diabetes mellitus (DM) [35], endometriosis (ENDO) 
[36], epilepsy [37], bladder cancer (BC) [38], benign pros-
tatic hyperplasia, (BPH) [39], osteoporosis (OP) [8], periph-
eral arterial occlusive disease (PAOD) [40], Parkinson’s dis-
ease (PD) [41], psoriasis (PSO) [42, 43], rheumatoid arthritis 
(RA) [44], overactive bladder (OAB) [45], systemic sclerosis 
(SSc) [46], multiple sclerosis (MS) [47] and schizophrenia 
(SCZ) [48]. The mean age of the patients was 55.87 years 
(SD = 17.75). More than half of patients were older than 
70 years in dementia, AMD, BPH and PAOD. More than 
half of the patients were female (n = 1356, 58.6%) and it 
is worthy of note that some studies involved exclusively 
female (endometriosis, osteoporosis, OAB) or male (BPH) 
patients. The mean disease duration in our sample was 8.75 
(SD = 8.95) years, with outstandingly high average disease 
duration in patients with psoriasis and epilepsy (Table 1).
Problems reported in the five EQ‑5D‑3L dimensions
In our sample, 519 patients (20.7%) did not report any 
problem in any of the five EQ-5D-3L dimensions, while 
420 (16.1%) reported problems (of any level) in all the 
five dimensions. Severe problems in at least one dimen-
sion were reported by 419 patients (17.6%), while 2002 
patients (82.4%) did not report the severe problem in any 
of the five dimensions.
The distribution of patients by problem levels and diag-
noses across the five EQ-5D-3L dimensions are presented 
in Fig. 1. Any problems were reported most frequently in 
dementia (96.5%), RA (95.2%), PAOD (95.2%) and AP 
(94.4%), while least frequently in endometriosis (44.3%), 
epilepsy (52.1%) and BPH (53.2%). Considering the total 
sample, the less affected health dimension was self-care 
with moderate and severe problems reported by 20.5% and 
2.6% of respondents, respectively. Most problems were 
indicated in the pain/discomfort dimension followed by 
anxiety/depression, with moderate problems reported by 
51.7% and 46.5%, and severe problems reported by 10.3% 
and 9.0%, respectively.
The percentage of patients reporting any problems 
in mobility, self-care, usual activities, pain/discomfort 
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and anxiety/depression was greatest in PAOD (89.3%), 
RA (56.2%), RA (20.9%), RA (8.4%) and SCZ (76.9%), 
respectively. Patients with dementia reported severe prob-
lems most frequently in the mobility (11.3%), self-care 
(19.7%), usual activities (36.1%) and anxiety/depression 
(30.2%) dimensions, while PAOD patients reported most 
frequently severe problems in the pain/discomfort dimen-
sion (31.1%) (Fig. 1).
Comparison of value sets by EQ‑5D‑3L dimensions
Figure 2 illustrates the relative importance of the EQ-5D-3L 
dimensions in the four value sets. Except for severe problems 
in the usual activities and pain/discomfort dimensions, the 
polish value set provided the highest values for health states 
with moderate or severe problems in a single dimension. For 
moderate problems, the Slovenian, while for severe ones the 
British value set provided the lowest values. The disutility 
of moderate problems compared to full health tended to be 
relatively small in the Polish and British value sets, followed 
by a steep decline between moderate and severe problem 
levels. However, in the Slovenian value set, the disutility of 
moderate problems tended to be greater, followed by a mod-
erate decline at severe problems. The differences between 
full health and moderate problems and between moderate 
and severe problems were similar in the European value 
set. The index values of health states with combined prob-
lems showed that compared to the TTO-based value sets 
the VAS-based Slovenian and European value sets tended 
to have lower index values in milder health states, while the 
Table 1  Main characteristics of the patient samples
ADHD attention-deficit/hyperactivity disorder, AMD age-related macular degeneration, BC bladder cancer, BPH benign prostatic hyperplasia, 
DM diabetes mellitus, ENDO endometriosis, NA not available, MS multiple sclerosis, OAB overactive bladder, OP osteoporosis, PAOD periph-
eral arterial occlusive disease, PsA psoriatic arthritis, PSO psoriasis, RA rheumatoid arthritis, SCZ schizophrenia, SSc systemic sclerosis
a Weighted mean and percentage values using analytical weights summing up to 100 in each disease
ICD-10 category/diagnosis Number 
of patients 
(n)
Age, mean (SD) Female, n (%) Disease duration 
(year), mean 
(SD)
EQ VAS mean (SD)
Diseases of the musculoskeletal system and connective tissue
 RA 249 55.38 (12.32) 214 (86.3%) 9.15 (9.33) 51.59 (19.90)
 PsA 177 49.89 (12.76) 101 (57.1%) 9.30 (9.24) 55.02 (19.87)
 SSc 80 57.39 (9.60) 72 (90.0%) 7.16 (6.63) 56.25 (18.73)
 OP 207 69.57 (8.93) 207 (100%) 7.49 (5.60) 59.20 (17.19)
Diseases of the nervous system
 Epilepsy 96 36.16 (12.12) 56 (58.3%) 15.38 (11.55) 73.84 (16.16)
 MS 68 37.96 (9.08) 48 (70.6%) 7.02 (5.90) 64.74 (22.18)
 PD 99 62.67 (11.32) 31 (33.0%) 8.08 (5.59) 59.47 (18.28)
Mental, behavioural and neurodevelopmental disorders
 Dementia 86 77.61 (8.60) 51 (60.0%) NA 48.59 (23.88)
 ADHD 75 30.44 (10.49) 17 (22.7%) NA 69.45 (19.43)
 SCZ 78 44.24 (13.05) 36 (46.2%) NA 60.01 (24.71)
Diseases of the genitourinary system
 ENDO 79 32.67 (4.80) 79 (100%) 7.68 (6.33) NA
 BPH 237 70.38 (8.18) 0 (0.0%) 5.53 (4.79) 68.44 (15.63)
 OAB 61 57.72 (11.56) 61 (100.0%) NA 62.80 (18.80)
Diseases of the skin and subcutaneous tissue
 PSO 192 50.49 (12.79) 61 (31.8%) 21.66 (11.77) 64.49 (21.52)
Neoplasms
 BC 148 66.24 (9.61) 50 (33.8%) 3.56 (3.78) 67.82 (19.35)
Endocrine, nutritional and metabolic diseases
 DM 264 61.31 (10.98) 151 (57.2%) NA 62.12 (19.95)
Diseases of the circulatory system
 PAOD 103 70.00 (10.21) 45 (43.7%) NA 45.75 (16.28)
Diseases of the eye and adnexa
 AMD 122 75.16 (7.88) 76 (62.3%) 2.94 (2.54) 58.59 (16.43)
Totala 2421 55.87 (17.75) 1356 (58.6%) 8.75 (8.95) 60.46 (20.74)
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UK and Polish value sets provided the lowest values for the 
combination of severe problems (33333). Among all 243 
EQ-5D-3L profiles, “worse than dead” health states with 
negative utility values were most prevalent in the British 
value set (35%), followed by the Polish (13%), the Slovenian 
(9%) and the European one (2%).
Considering severe problems, the Polish and British value 
sets provided the largest decrease of health state value in the 
pain/discomfort dimension. In contrast, severe problems in 
the mobility dimension had the highest negative impact on 
the EQ-5D-3L index value in the European and the Slove-
nian value sets. Based on these findings, we expected that 
both the overall severity and the main problem domains of 
certain conditions would contribute to the utility differences 
demonstrated between the four value sets.
Comparison of value sets by diagnosis
To conduct our analysis by diagnosis, we calculated the EQ-
5D-3L index scores (mean, standard deviation) with all the 
four value sets for each diagnosis. The weighted mean EQ-
5D-3L index scores in our total sample were, respectively, 
0.598 (SD = 0.279), 0.661 (SD = 0.257), 0.770 (SD = 0.261) 
and 0.644 (SD = 0.334) with the Slovenian, European, Polish 
and British value sets. All pairwise value set comparisons 
were significant (p < 0.001). Patients with endometriosis had 
the highest, while dementia patients had the lowest mean 
EQ-5D-3L scores in all four value sets. The most significant 
difference between any two value sets was found in PD: the 
difference between the Slovenian and Polish index values 
was 0.265. The pairwise comparisons of the four value sets 
by two-sided t tests showed highly significant differences in 
most diagnoses. In SCZ, the British value set did not differ 
significantly from the Slovenian and European value sets. In 
other diagnoses, five or six pairwise value set comparisons 
were significantly different. The British and European value 
sets did not differ significantly in 10, and the British and 
Slovenian in 2 out of the 18 diagnoses. All other value set 
comparisons showed significant differences in all diagnoses 
(Table 2).
Comparison of value sets by patients’ subjective 
health assessment
We explored how disease severity influenced the differences 
between value sets. As a proxy for disease severity, we used 
subjective health assessments by the EQ VAS. We observed 
three distinct EQ VAS regions based on the pattern of value 
set differences (Fig. 3). Across the entire EQ VAS range, 
the Polish index values were highest. We observed greatest 
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Fig. 1  Problems reported in the five EQ-5D-3L dimensions by diag-
nosis. ADHD attention-deficit/hyperactivity disorder, AMD age-
related macular degeneration, BC bladder cancer, BPH benign pros-
tatic hyperplasia, DM diabetes mellitus, ENDO endometriosis, MS 
multiple sclerosis, OAB overactive bladder, OP osteoporosis, PAOD 
peripheral arterial occlusive disease, PsA psoriatic arthritis, PSO pso-
riasis, RA rheumatoid arthritis, SCZ schizophrenia, SSc systemic scle-
rosis
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differences between the four value sets in the EQ VAS range 
between 40 and 80 (n = 437, 61.7%). In this range, the Slo-
venian index values were lowest, while the European and 
British value sets provided nearly identical index values. 
Differences were the smallest in the EQ VAS range between 
80 and 100 (n = 437, 20.4%), and the pattern of value sets 
changed below EQ VAS levels of 40 (n = 437, 17.9%), where 
the Slovenian, European and Polish value sets converged, 
and the British value set provided the lowest index values.
Comparison of value sets by age groups
We aimed to analyse whether the EQ-5D-3L index scores 
calculated with the four value sets differed depending on the 
patients’ age. Three age groups were created: 18–34, 35–54 
and 55+ years old. From the 2421 patients 16.3% belonged 
to the youngest (n = 275), 26.7% to the middle (n = 609) and 
56.6% (n = 1525) to the oldest age group.
More than half of the patients belonged to the youngest 
age group in ADHD (69.3%), endometriosis (64.6%) and 
epilepsy (54.2%). In certain diseases that typically affect 
the elderly, most of the patients were over 55 years old. In 
AMD 100%, in dementia 96.5%, in BPH 95.8%, in PAOD 
95.2% and in OP 93.7% of the patients belonged to the old-
est age group.
The Slovenian, European, Polish and British index val-
ues were 0.765 (SD = 0.214), 0.793 (SD = 0.190), 0.886 
(SD = 0.140) and 0.804 (SD = 0.213) in the 18–34 age group, 
0.601 (SD = 0.277), 0.662 (SD = 0.255), 0. 773 (SD = 0.251) 
and 0.644 (SD = 0.329) in the 35–54 age group, and 0.548 
(SD = 0.277), 0.622 (SD = 0.262), 0.735 (SD = 0.281) and 
0.598 (SD = 0.350) in the 55+ age group, respectively. All 
value set comparisons differed significantly (p ≤ 0.001). In 
all age groups, index values were lowest when measured 
with the Slovenian, followed by the European and the British 
value sets, while the Polish index values were highest. The 
difference between index values of the youngest and eldest 
age groups was biggest when using the Slovenian (0.217), 
followed by the British (0.206), the European (0.171) and 
the Polish (0.150) value sets. All age group comparisons 
were significant (p < 0.001).
The sensitivity of disease burden evaluation 
to the choice of the value set
Although the British TTO value set is used most frequently 
for the evaluation of health outcomes in Hungary as well 
as the CEE region [8, 51], we explored how DB evalua-
tions would be affected in the 18 conditions by choosing 
a different value set (Fig. 4). We observed differences in 
both positive and negative directions in certain conditions 
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Fig. 2  EQ-5D-3L index scores for selected health states by the four different value sets
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with all value sets, with most striking differences between 
the British and Slovenian ones. The DB score of dementia 
was nearly 0.15 index points lower, while for MS and PD 
nearly 0.05 index points higher when choosing the Slovenian 
value set instead of the British one. The Polish value set 
differed most from the British one in PsA, while the Euro-
pean one in dementia. The difference was also substantial 
between the Polish and Slovenian value sets in MS and PD 
as well. The value sets performed nearly identically in DM, 
epilepsy, OAB and OP. The difference from the British value 
set tended to increase with the level of disease burden in all 
value sets.
As a general measure of sensitivity to the choice of the 
value set, we introduced the sensitivity index (Table 3). 
Altogether, from the 153 pairwise comparisons of DB scores 
that were evaluated between the 18 conditions (n = 18*17/2), 
22.9% provided diverse outcomes. Most of the diverse out-
comes were combinations of non-significant differences and 
significant differences in one direction. Mainly due to the mod-
est sample sizes of the disease subsamples, there were no pair-
wise comparisons where alternative value sets provided statis-
tically significant reverse DB rankings. (+ ΔDBij for one value 
set, but—for another.) The sensitivity index suggested that the 
disease conditions are not identically sensitive to the choice of 
the value set. The outcome of DB comparisons including con-
ditions such as dementia, MS or PAOD depended strongly on 
the value set, while DB comparisons of other diseases, such as 
BPH and BC, were hardly affected. The sensitivity index also 
Table 2  EQ-5D-3L index scores by diagnosis
ADHD attention-deficit/hyperactivity disorder, AMD age-related macular degeneration, BC bladder cancer, BPH benign prostatic hyperplasia, 
DM diabetes mellitus, ENDO endometriosis, EU European, NA not available, MS multiple sclerosis, OAB overactive bladder, OP osteoporosis, 
PAOD peripheral arterial occlusive disease, PL polish, PsA psoriatic arthritis, PSO psoriasis, RA rheumatoid arthritis, SCZ schizophrenia, SI 
Slovenian, SSc systemic sclerosis, UK British
a Weighted mean and percentage values using analytical weights summing up to 100 in each disease
Patients, ICD-10 
categories and diag-
noses
EQ-5D-3L index score, mean (SD) Two-sided paired t test p values
SI EU UK PL SI-EU SI-PL SI-UK PL-UK PL-EU UK-EU
Diseases of the musculoskeletal system and connective tissue
 RA 0.411 (0.217) 0.506 (0.235) 0.464 (0.334) 0.646 (0.270) < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
 PsA 0.423 (0.230) 0.513 (0.244) 0.467 (0.347) 0.645 (0.288) < 0.001 < 0.001 0.002 < 0.001 < 0.001 < 0.001
 SSc 0.486 (0.240) 0.583 (0.218) 0.580 (0.285) 0.736 (0.234) < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 0.770
 OP 0.519 (0.242) 0.603 (0.233) 0.580 (0.319) 0.729 (0.258) < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 0.002
Diseases of the nervous system
 Epilepsy 0.804 (0.229) 0.826 (0.210) 0.831 (0.244) 0.900 (0.166) 0.001 < 0.001 0.006 < 0.001 < 0.001 0.384
 MS 0.586 (0.252) 0.670 (0.222) 0.669 (0.278) 0.795 (0.195) < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 0.870
 PD 0.476 (0.240) 0.583 (0.226) 0.588 (0.281) 0.741 (0.202) < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 0.523
Mental, behavioural and neurodevelopmental disorders
 Dementia 0.381 (0.288) 0.424 (0.286) 0.333 (0.430) 0.523 (0.405) < 0.001 < 0.001 0.023 < 0.001 < 0.001 < 0.001
 ADHD 0.697 (0.188) 0.727 (0.175) 0.735 (0.222) 0.846 (0.142) < 0.001 < 0.001 0.005 < 0.001 < 0.001 0.320
 SCZ 0.626 (0.214) 0.658 (0.212) 0.644 (0.295) 0.778 (0.227) 0.002 < 0.001 0.320 < 0.001 < 0.001 0.261
Diseases of the genitourinary system
 ENDO 0.880 (0.146) 0.888 (0.136) 0.902 (0.124) 0.950 (0.066) 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
 BPH 0.792 (0.228) 0.838 (0.181) 0.852 (0.187) 0.913 (0.114) < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
 OAB 0.611 (0.256) 0.678 (0.227) 0.668 (0.314) 0.787 (0.253) < 0.001 < 0.001 0.005 < 0.001 < 0.001 0.489
Diseases of the skin and subcutaneous tissue
 PSO 0.647 (0.271) 0.706 (0.246) 0.694 (0.310) 0.808 (0.226) < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 0.056
 Neoplasms
 BC 0.729 (0.236) 0.775 (0.205) 0.784 (0.242) 0.874 (0.152) < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 0.051
Endocrine, nutritional and metabolic diseases
 DM 0.665 (0.276) 0.728 (0.243) 0.723 (0.295) 0.826 (0.220) < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 0.350
 Diseases of the circulatory system
 PAOD 0.413 (0.252) 0.508 (0.274) 0.426 (0.411) 0.589 (0.359) < 0.001 < 0.001 0.527 < 0.001 < 0.001 < 0.001
Diseases of the eye and adnexa
 AMD 0.622 (0.262) 0.679 (0.250) 0.657 (0.334) 0.780 (0.246) < 0.001 < 0.001 0.013 < 0.001 < 0.001 0.020
Totala 0.598 (0.279) 0.661 (0.257) 0.644 (0.334) 0.770 (0.261) < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
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provided information about how the choice between two value 
sets influenced DB evaluation results across the 18 conditions. 
Overall, the Slovenian and Polish value sets provided the most 
divergent DB comparisons: in 21.2% of the DB comparisons, 
the choice between the Slovenian and Polish value sets pro-
vided a divergent outcome. At the other extreme, the choice 
between the European and Slovenian value sets hardly affected 
the outcome of DB comparisons, just as the choice between 
the Polish and the British value sets.
Discussion
We analysed the systematic differences between four value 
sets and their potential impact on health priority setting 
across 18 chronic conditions [8, 31–48]. We chose value 
sets that are mostly used or potentially applicable to health 
economic evaluations in the CEE region [8]. Our analy-
sis was conducted on a broad range of immune-mediated 
inflammatory diseases, neurological, mental, urological 
and other disorders from cross-sectional samples recruited 
Fig. 3  Comparison of value sets 
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in Hungary [8, 31–48]. We compared patient-level utility 
values using the four value sets in each condition with 
individual-level data from a population-norm for the CEE 
region. Former studies compared different TTO and VAS-
based EQ-5D-3L value sets among the general populations 
of different countries [11], TTO-based value sets from dif-
ferent econometric models on a single patient population 
[12, 52], three TTO-based value sets in a single general 
population [53] and composite TTO (cTTO) and discrete-
choice experiment (DCE) based value sets from six coun-
tries across seven patient populations [54]. Numerous 
studies compared value sets by each EQ-5D-3L profile 
[13, 29, 55]. Our study is unique in terms of comparing 
value sets derived by different methods (VAS and TTO) 
from populations with different cultural and economic 
background (CEE and Western Europe) across multiple 
patient populations. Although the 18 conditions were cho-
sen arbitrarily, the breadth of disease areas, as well as the 
severity of conditions, allowed for a unique systematic 
comparison of disease burden estimates that allows the 
generalisation of our results beyond the boundaries of the 
Hungarian healthcare system.
Table 3  Sensitivity of DB comparisons to the choice of value set (sensitivity index)
ADHD attention-deficit/hyperactivity disorder, AMD age-related macular degeneration, BC bladder cancer, BPH benign prostatic hyperplasia, 
DM diabetes mellitus, ENDO endometriosis, EU European, NA not available, MS multiple sclerosis, OAB overactive bladder, OP osteoporosis, 
PAOD peripheral arterial occlusive disease, PL polish, PsA psoriatic arthritis, PSO psoriasis, RA rheumatoid arthritis, SCZ schizophrenia, SI 
Slovenian, SSc systemic sclerosis, UK British
a Calculated from 17×4 DB evaluations
b Calculated from 153×4 DB evaluations
c Calculated from 17×2 DB evaluations
d Calculated from 153×2 DB evaluations
Number of com-
parisons
Proportion of inconsistent pairwise DB differences based on comparing
All four value 
 setsa
EU vs. PL 
value  setc
EU vs. SI 
value  setc
EU vs. UK 
value  setc
SI vs. PL 
value  setc
SI vs. UK 
value  setc
PL vs. UK 
value  setc
Diseases of the musculoskeletal system and connective tissue
 RA 17 0.118 0.059 0.000 0.059 0.118 0.118 0.000
 PsA 17 0.176 0.118 0.000 0.118 0.118 0.118 0.000
 SSc 17 0.294 0.294 0.000 0.176 0.294 0.176 0.118
 OP 17 0.235 0.235 0.000 0.118 0.235 0.118 0.118
Diseases of the nervous system
 Epilepsy 17 0.118 0.059 0.000 0.000 0.059 0.118 0.059
 MS 17 0.412 0.235 0.059 0.059 0.412 0.235 0.176
 PD 17 0.294 0.294 0.000 0.294 0.294 0.294 0.000
Mental, behavioural and neurodevelopmental disorders
 Dementia 17 0.412 0.235 0.118 0.235 0.412 0.412 0.000
 ADHD 17 0.294 0.294 0.000 0.294 0.294 0.294 0.000
 SCZ 17 0.294 0.294 0.000 0.118 0.235 0.059 0.176
Diseases of the genitourinary system
 ENDO 17 0.176 0.118 0.059 0.000 0.118 0.118 0.118
 BPH 17 0.000 0.000 0.000 0.000 0.000 0.000 0.000
 OAB 17 0.294 0.294 0.000 0.235 0.294 0.235 0.059
Diseases of the skin and subcutaneous tissue
 PSO 17 0.294 0.235 0.118 0.235 0.235 0.235 0.000
Neoplasms
 BC 17 0.059 0.000 0.059 0.000 0.059 0.059 0.000
Endocrine, nutritional and metabolic diseases
 DM 17 0.118 0.059 0.000 0.000 0.118 0.059 0.059
Diseases of the circulatory system
 PAOD 17 0.353 0.353 0.000 0.235 0.353 0.235 0.118
Diseases of the eye and adnexa
 AMD 17 0.176 0.059 0.118 0.059 0.176 0.176 0.000
Total 153 0.229b 0.180d 0.029d 0.124d 0.212d 0.170d 0.056d
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We found remarkable differences across diagnoses, age 
groups or patients with different disease severity. For exam-
ple, the mean EQ-5D-3L index difference was as high as 
0.265 in PD and 0.187 in the 55 + age group. The systematic 
pairwise comparison of DB evaluations between all disease 
conditions revealed inconsistent results between value sets 
determined via the VAS and TTO valuation methodology. 
The proportion of discrepant DB evaluations was 21.9% 
when comparing the Slovenian VAS and Polish TTO value 
sets. However, value sets determined via the same method-
ology provided rather consistent results. Only 2.9% of DB 
evaluations were discrepant when comparing the VAS-based 
Slovenian and European value sets, and 5.6% when compar-
ing the TTO-based Polish and British value sets, despite 
the apparent cultural or economic differences between the 
populations whose preferences were valued. Our results 
confirm the findings of previous studies highlighting the 
methodology-driven differences between EQ-5D-3L value 
sets [11, 54].
The differences between EQ-5D-3L value sets can lead to 
significant differences in health gains in EQ-5D-3L-based 
cost-utility analyses. Taking the extremes, for example, if the 
health status of a patient is improved from ‘22222’ (moder-
ate problems in all dimensions) to ‘11111’ (perfect health) 
over a year with a new treatment, the QALY gain will be 
0.685 with the Slovenian, but only 0.284 with the Polish 
value set. Improvement from the worst possible health state 
(‘33333’) to a moderate health state (‘22222’) would result 
in 1.239 QALY gain with the Polish, but only 0.555 with the 
European value set. Results of the DB evaluations and the 
examples for the potential QALY-gain differences pinpoint 
that the value set chosen to calculate health state utilities 
in chronic diseases might significantly influence the results 
as well as the health policy and financing decisions. These 
findings deserve careful consideration in health economic 
analyses in the CEE, where local data are sparse, and eco-
nomic analyses frequently need to rely on a variety of exter-
nal sources. [56].
There is increasing interest in developing country-specific 
value sets. Local value sets could reflect better the health 
preferences of a given population (people’s beliefs about 
how particular problems in the EQ-5D dimensions impact 
their health-related quality of life) than value sets derived 
in a foreign country [57]. By feeding into further analyses, 
major utility score differences owing to the choice of value 
set can contribute to disparities in health policy and financ-
ing decisions due to over- or underestimation of treatment 
outcomes or different prioritisation of diseases. Although 
populations’ preferences might be reflected better by coun-
try-specific value sets, international comparisons of access 
differences, for example, are getting difficult to interpret and 
less useful for policymaking as it may be difficult to dis-
entangle disparities between countries driven by different 
evaluations of disease burden or treatment outcomes, or 
other factors related to the local healthcare system. Hence, 
using a single value set, adjusted [58] or even unweighted 
scores [59, 60] would aid cross-country comparisons by 
diminishing the effect of differences arising from different 
methodologies or health preferences.
The differences of the value sets might at least partly 
explain the differences between Poland and Hungary in 
terms of access to highly effective but costly biological 
drugs in chronic immune-mediated diseases. Several stud-
ies were conducted involving these two countries in CEE 
to evaluate access to biologicals in rheumatoid arthritis, 
psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, 
ulcerative colitis and psoriasis. [33, 61–63]. Although the 
access to biologicals correlated strongly with GDP per 
capita among European countries [64], substantial differ-
ences were found in the uptake among countries with similar 
economic development such as Poland and Hungary [33]. 
Access to biologicals varies widely among CEE countries, 
and this difference could not be explained by epidemiologi-
cal factors, drug prices or total health expenditure.
Variations of reimbursement policy may be one of the 
factors explaining the differences to a certain extent in Bul-
garia, Latvia, Lithuania, and Poland, but the association with 
other possible.
Determinants (differences in prevalence and incidence, 
the price of biologicals, total expenditure on health, geo-
graphical access, and cost-effectiveness results) were not 
proven. We assumed, nevertheless, in these papers that 
health deterioration linked to these diseases might be val-
ued differently against other systemic inflammatory condi-
tions in distinct countries and which may contribute to the 
immense diversity in the utilisation of biological drugs for 
immune-mediated chronic diseases. However, comparison 
of Hungary and Poland which have very similar total health 
expenditure refutes this assumption since in Hungary the 
exposure to biologicals used to be approximately ten times 
higher compared to Poland in inflammatory bowel diseases 
[51], despite the chronic financial deficits of the Hungarian 
healthcare system [65]. Similar differences were seen using 
biologics in psoriasis [63] and rheumatoid disorders [62, 
66].
In addition to the availability of patient-level data from 18 
conditions, a unique strength of our study is that we could 
calculate disease burden scores with the four value sets using 
population norm database involving patient-level data of 
6926 respondents. Our database contained 997 individuals 
in the 65+ age group, allowing for potentially more reliable 
DB estimates in older populations than the available local 
population norm values [4, 5]. However, our analysis has 
some limitations. The patients included in our sample may 
not be representative of the entire patient population in the 
given diagnosis. Further research including other diseases 
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could help to understand in condition-specific differences 
that can be detected in the EQ-5D-3L index values calcu-
lated with different value sets. Comparison with other value 
sets could aid a better understanding of the factors influenc-
ing the differences between national value sets coming from 
different regions.
As a conclusion, based on the analysis of a wide range 
of chronic conditions and a variety of value sets in terms of 
the population and method of valuation, our study highlights 
the potential impact of value set choice on health policy 
decisions.
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